moneyheap
ARGX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is argenx SE American Depositary Shares (ARGX) stock moving?
Two positive company-specific events landed on Nov 9 and the stock rallied with them. The Phase 3 ALKIVIA study met its primary endpoint in the combined IMNM and DM population, with a 15.4-point greater TIS improvement versus placebo at Week 52 (p=0.0011). IMNM showed a 14.8-point gain (p=0.0048), and argenx plans to file a supplemental BLA by end-2026, which could make efgartigimod the first targeted treatment for IMNM. The same day, argenx agreed to buy the rest of Unnatural Products for up to about $1.15B, of which $550M is upfront in cash; this is roughly 1% of the roughly $58.3B market cap. Analyst support is intact: JPMorgan reiterated Overweight with a 950 euro target. Price action confirms the news: ARGX closed at 971.55 on Nov 10, up about 10.9% from the Oct 22 close of 875.76, and up about 8.6% from 894.77 on Nov 5. It hit new highs in the window on Nov 9 and Nov 10. Volume has been moderate, around 300,000 to 650,000 shares a day since Oct 23, with the largest volume in the window on Oct 22 (about 1.02M, likely the Q3 report day). Risks remain: the ALKIVIA DM result was consistent rather than separately significant, the deal adds integration and spending load, and the Oct 29 Pomerantz investigation after a discontinued Phase 3 study is a reputational overhang. The price has already moved sharply, so near-term upside depends on the Nov 11 ACR presentation and any follow-up data.
News behind the analysis
- argenx to Acquire Unnatural Products for Up to $1.15 Billionargenx agreed to acquire the remaining shares of Unnatural Products (UNP) for up to about $1.15 billion, including a $550 million upfront cash payment. The deal adds a macrocyclic peptide discovery platform.
- Argenx To Acquire Unnatural Products For Up To ~$1.15B Including $550M Upfront And Up To $595M In Milestones, Adding Peptide Discovery EngineBenzinga details the deal structure: $550 million upfront and up to $595 million in milestone payments. UNP will keep operating from Santa Cruz, California.
- Reported Saturday, argenx Plans To Submit Supplemental BLA For Efgartigimod In IMNM By End Of 2026 After Phase 3 ALKIVIA Shows 14.8-Point Greater TIS Improvement Versus Placebo At Week 52The Phase 3 ALKIVIA study showed a 14.8-point greater Total Improvement Score versus placebo at Week 52 in IMNM. argenx plans to submit a supplemental BLA for efgartigimod in IMNM by the end of 2026.
- If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Todayargenx has outperformed the market over five years by 15.47% annualized, with an average annual return of 25.51%. Market capitalization is about $58.31 billion.
- JPMorgan Maintains Overweight Rating on argenx SEJPMorgan reiterated its Overweight rating and 950 euro price target after reviewing the company's recent quarterly results.
- argenx to Present at Upcoming Investor Conferences in November 2026Management will attend the Guggenheim 3rd Annual Healthcare Innovation Conference and the Jefferies London Global Healthcare Conference in November 2026.
- Pomerantz LLP Investigates Securities Claims Against argenx SEPomerantz LLP announced an investigation into argenx over possible securities or unlawful business practices after the company discontinued a Phase 3 study. This is a law-firm notice, not a filed lawsuit.
- argenx Named Among Top 5 Large Employers in BioSpace's 2027 Best Places to Work Listargenx was named one of the top five large employers in the biopharmaceutical industry in BioSpace's 2027 Best Places to Work rankings.
About argenx SE American Depositary Shares
argenx is a Dutch-Belgian immunology biotech, listed on Euronext and on Nasdaq through ADRs, that makes medicines for severe autoimmune diseases. Its main product is VYVGART (efgartigimod), a leading FcRn-blocking antibody for generalized myasthenia gravis and CIDP, the chronic nerve disorder chronic inflammatory demyelinating polyneuropathy.
How it makes money
Almost all of its revenue comes from sales of VYVGART (given into a vein) and VYVGART Hytrulo (injected under the skin). Third-quarter 2026 product sales were about $1.7 billion, up roughly 54% from a year earlier, and sales for the first nine months of 2026 were about $4.5 billion. It earns a small amount of other operating income. It spends heavily on research and on selling the drug worldwide.
What usually moves ARGX
- VYVGART sales growth and patient uptake
- Label expansions and FDA decisions (e.g., ocular MG, myositis)
- Pipeline readouts such as empasiprubart in MMN
- Competition from rival FcRn drugs
- Acquisitions like Forte Biosciences (FB102)